tirzepatide fda shortage update backtracks over Eli Lilly weight-loss drug FDA confirms tirzepatide shortage is

GLP-1 Drugs: FDA Sued Over Removing Tirzepatide from the Drug Shortage List Less than a week after the U.S

The FDA has sent several warning letters to GLP-1 compounders using salts, as well as companies selling drugs with non-FDA-approved peptide therapies retatrutide and cagrilintide for weight loss, over the last few years

Sure, this sounds bad initially, but this kind of muscle loss isnt unique to GLP-1s

Pickart L, Margolina A Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data International Journal of Molecular Sciences (2018) 2

What the menopause transition specifically causes is a redistribution of fat to the abdomen (visceral fat) plus loss of muscle mass even when weight stays the same